Surprise As Amgen Passes Regeneron/Sanofi To First PCSK9 Inhibitor Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
While all eyes were on the U.S. market, Amgen clinched victory over Regeneron/Sanofi in the race to be first to approval with a PCSK9 inhibitor in another major territory, the EU.